Labcorp has introduced a new AI-driven real world data platform developed in collaboration with Amazon Web Services (AWS) and Datavant. The solution enables rapid analysis of large, de-identified healthcare datasets to speed up Alzheimer’s disease research, drug development, and clinical trial recruitment.
Glimpse:
Announced on April 14, 2026, the platform integrates diagnostic, genomic, and claims data from millions of patients using agentic AI models. It allows researchers, biopharmaceutical companies, payers, and contract research organizations to generate insights in minutes instead of months. Initial validation for Alzheimer’s will conclude in spring 2026, with plans to expand to other therapeutic areas including inflammatory diseases, cardiometabolic conditions, women’s health, and oncology. It leverages AWS services like Amazon Bedrock and Amazon SageMaker.
Labcorp, a global leader in laboratory services, has launched an innovative AI-powered real world data platform in partnership with Amazon Web Services and Datavant to transform the pace of Alzheimer’s disease research and drug development. The platform addresses longstanding challenges in healthcare data analysis, where fragmented systems and manual processing often delay insights for months. By combining de-identified datasets with advanced artificial intelligence, it now enables users to uncover meaningful patterns and generate actionable results in just minutes.
The solution draws on Labcorp’s extensive longitudinal laboratory data, along with genomic and claims information, and will soon incorporate electronic health records and social determinants of health. Using agentic AI models, the platform helps identify suitable patient cohorts for clinical trials based on specific inclusion and exclusion criteria, tracks disease progression across diverse populations, measures treatment outcomes, and highlights unmet clinical needs through statistical modeling. This capability is particularly valuable in Alzheimer’s research, where more than 7.2 million Americans are affected and annual care costs exceed $380 billion in the United States.
Researchers, biopharmaceutical companies, payers, and contract research organizations can now access privacy protected, linked datasets to accelerate scientific discovery and improve trial recruitment efficiency. The platform’s design reduces time spent on data engineering, allowing experts to concentrate on core scientific work and ultimately bring new therapies to patients faster.
The initial validation phase for the Alzheimer’s focused application is expected to wrap up in spring 2026. Following successful testing, the platform will expand its scope to additional disease areas such as inflammatory conditions, cardiometabolic disorders, women’s health, and oncology throughout the year. This launch forms part of Labcorp’s broader strategy to leverage AI and real world evidence for more efficient and equitable healthcare research
“The platform significantly reduces the time required for data preparation and allows researchers to focus more on scientific discovery rather than data engineering.”
By
HB Team
Related News
